NCT03508752: Neurocognitive Decline in Patients With Brain Metastases

NCT03508752
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER++, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Ph+ase 1|Ph+ase 2
Drug Category: Radiation therapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years to 120 Years (Adult, Older Adult)
Location of Metastases: Brain
Additional Notes: Patients must have 6+ metastases with largest tumor no larger than 4 cm
Exclusions: Patients with leptomeningeal metastasis or prior WBRT
https://ClinicalTrials.gov/show/NCT03508752

Comments are closed.

Up ↑